Shots:

• IRLAB to receive ~$363M- including $28M as up front and ~$335M as development- regulatory and commercial milestones along with royalties on WW net sales of mesdopetam
• Ipsen get the exclusive WW rights to develop and commercialize mesdopetam (novel dopamine D3-receptor antagonist) which is currently being evaluated in P- IIb clinical trials for patients with PD experiencing LID
• IRLAB will be responsible for the ongoing P-IIb trial while Ipsen will initiate P- III preparatory activities- and is responsible for all remaining clinical development and commercialization globally

  Ref: Ipsen | Image: Genetic Engineering and Biotechnology News